CalciMedica (CALC) Fundamentals 2026 — Revenue Analysis | SniperIQ
CalciMedica (CALC) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CalciMedica's market cap?
CalciMedica (CALC) has a market capitalization of approximately
How profitable is CalciMedica?
CalciMedica runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does CalciMedica pay a dividend?
CalciMedica does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is CalciMedica financially healthy?
CalciMedica carries a debt-to-equity ratio of 0.00x and a current ratio of 1.61x, with a market beta of 1.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CalciMedica a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CalciMedica (CALC) the key facts are: market cap
Track CalciMedica's full fundamentals live
Get CalciMedica's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.